Journal Of Clinical Oncology (jco) Podcast

Summarize the paper by Asselin et al and review the risks of therapy-related cardiomyopathy and evidence supporting dexrazoxane use in pediatric oncology.

Recent findings represent an important and exciting step in applying the rapid advance of sequencing technologies to generate molecularly-driven approaches towards the detection of gynecologic malignancies.  More work is needed to better define and validate where such an approach might add most meaningfully in the search for effective methods of ovarian and endometrial cancer detection and diagnosis.

This podcast discusses the study by Hennink and colleagues regarding their randomized controlled trial of a 3-year versus 6-year interval for screening colonoscopies in individuals with a family history of colorectal cancer.

The randomized placebo controlled trial of progesterone receptor blockade showed no difference in survival, finally answering the question about hormonal therapy in this disease and raising new questions about how to move forward quickly.

This podcast reviews the current knowledge of staging and prognosis of mycosis fungoides and Sezary syndrome and evaluates the CLIC study, which aims to develop a prognostic index that can be used with patients who are diagnosed with advanced disease.

This podcast summarizes new evidence about the role of travel distance, oncologist density, and insurance in receipt of guideline-based chemotherapy for patients with stage III colon cancer.

This podcast will discuss the association of obesity and risk of developing colorectal cancer in Lynch syndrome patients based on a manuscript by Mohammad Movahedi and colleagues. In this manuscript, they report an association between obesity and increased risk of colorectal cancer as well as the potential benefit of aspirin to reduce the risk of colorectal cancer in obese Lynch syndrome patients.

Combined analysis of multiple phase three trials in multiple myeloma demonstrates improved outcomes with continued therapy

This podcast will examine data on utilization, toxicity and survival outcomes with the use of intraperitoneal chemotherapy for initial treatment of ovarian cancer at six NCCN institutions.

Analogous to prior analyses with ABVD, in a large series of Hodgkin lymphoma patients treated with BEACOPP, Haverkamp and colleagues from the German Hodgkin Study Group report that early discontinuation of bleomycin or vincristine due to toxicity has no impact on cure rates or survival.

This podcast explores the complicated relationship between potency, toxicity, and duration of therapy, and how each impacts the overall efficacy of therapy.

This study involved working together across oceans, regulatory bodies in various countries, different cultures in 4 cooperative groups, different standard chemotherapy administration guidelines, and putting aside personal biases and styles to work together and come up with a document acceptable to all, in order to conduct an international trial in a rare disease for the benefit of children with osteosarcoma.

The two recent papers by Kitagawa, et al and Rose, et al, give us treatment options and tools that help maximize not only the benefits of survival with treatment but minimization of non-beneficial treatment toxicity through identification of patients with advanced and recurrent cervical cancer that are most and least likely to benefit.

This podcast places the results of SWOG S0809, a phase II intergroup trial of adjuvant capecitabine/gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma, in context with prior conflicting data and discusses implications for development of a definitive phase III trial.

This is a well-annotated study demonstrating that men treated with androgen deprivation therapy for prostate cancer have impaired cognitive performance within six months of starting therapy and that a specific genetic polymorphism may lend toward greater susceptibility to cognitive impairment.

This is a requested commentary regarding a concurrently-published manuscript which evaluated the utility of omega-2 fatty acids for the treatment of aromatase inhibitor-associated arthralgias.

A meta-analysis of 7 randomized trials comparing EGFR kinase inhibitors to chemotherapy for advanced EGFR-mutant lung cancer has shown that some populations gain greater benefit from targeted therapy – namely never-smokers, woman, and tumor harboring exon 19 deletions.

This podcast discusses a novel immunotherapy approach using an allogeneic whole tumor cell vaccine to prime, and a recombinant antigen-encoded bacterial vector to boost, immune responses against pancreatic cancer and explains why this approach may be beneficial in the treatment of advanced pancreatic cancer.